MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.160
-0.110
-2.58%
Opening 13:53 09/22 EDT
OPEN
4.240
PREV CLOSE
4.270
HIGH
4.260
LOW
4.160
VOLUME
17.98K
TURNOVER
--
52 WEEK HIGH
13.34
52 WEEK LOW
2.920
MARKET CAP
15.36M
P/E (TTM)
-1.3976
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (Nasdaq:BPTH)
DALLAS, TX / ACCESSWIRE / September 18, 2020 / Bio-Path Holdings, Inc.
ACCESSWIRE · 4d ago
Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive
GlobeNewswire · 09/09 12:00
Hancock Jaffe Laboratories leads healthcare gainers: Organovo leads the losers
Gainers: Hancock Jaffe Laboratories (HJLI) +83%. Bio-Path Holdings (BPTH) +22%. Harpoon Therapeutics (HARP) +21%. Fluidigm (FLDM) +15%. Midatech Pharma (MTP) +13%.Losers: Organovo (ONVO) -10%. Akers Biosciences (AKER) -9%. Trevena (TRVN) -9%. OpGen (OPGN) -9%. Axcella Health
Seekingalpha · 08/21 15:03
Bio-Path Holdings Shares Resume Trading; Up 30%
Benzinga · 08/21 14:49
Bio-Path Holdings Shares Halted On Volatility
Benzinga · 08/21 14:44
Bio-Path shares are trading lower as a potential sell-off after the stock increased roughly 25% on Friday's trading session. HC Wainwright & Co lowered its price targets from $18 to $12 per share.
Benzinga · 08/17 16:50
Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript
Bio-Path Holdings Inc (NASDAQ:BPTH) Q2 2020 Results Conference Call August 14, 2020 08:30 AM ET Company Participants Will O’Connor - Stern Investor Relations Peter Nielsen - President, Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Laura Ingalls - Stone Gate Capital Partners Yi Chen - H.C.
Seeking Alpha - Transcript · 08/14 15:56
Bio-Path EPS beats by $0.41
Bio-Path (BPTH): Q2 GAAP EPS of -$0.55 beats by $0.41.Cash of $14.4M"We look forward to initiating a Phase 1 study of prexigebersen for the treatment of solid tumors by year
Seekingalpha · 08/14 11:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPTH stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 754.32K
% Owned: 20.43%
Shares Outstanding: 3.69M
TypeInstitutionsShares
Increased
2
1.52K
New
4
4.72K
Decreased
7
138.72K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.20%
Pharmaceuticals & Medical Research
-0.07%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Martina Molsbergen
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average BPTH stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.